Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases

Journal of Viral Hepatitis

Volumn 11, Issue 4, 2004, Pages 358-365

  Georgiadou, S P ^a   Zachou, K ^a   Rigopoulou, E ^a   Liaskos, C ^a   Mina, P ^a   Gerovasilis, F ^b   Makri, E ^a   Dalekos, G N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b General Hospital of Volos   (Greece)

Author keywords

Chronic hepatitis C; HBV DNA; Hepatitis B virus; Hepatitis C virus; Nonviral hepatic diseases; Occult HBV infection

Indexed keywords

ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B VIRUS ANTIGEN; HEPATITIS C VIRUS ANTIGEN; MARKER; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD DONOR; CHRONIC HEPATITIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DONOR; EPIDEMIOLOGICAL DATA; ETHNIC GROUP; FEMALE; HEALTH STATUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OCCULT HEPATITIS B INFECTION; PATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERUM;

ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; GREECE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 3242721272     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00513.x     Document Type: Article

References (51)

1. Lee DS, Huh K, Lee EH, Lee DH, Hong KS, Sung YC. HCV and HBV coexist in HBsAg-negative patients with HCV viraemia: possibility of coinfection in these patients must be considered in HBV-high endemic area. J Gastroenterol Hepatol 1997; 12: 855-861.
2. Zarski JP, Bohn B, Bastie A et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
3. Pontisso P, Gerotto M, Benvegnu L, Chemello L, Alberti A. Coinfection by hepatitis B virus and hepatitis C virus. Antivir Ther 1998; 3 (Suppl. 3): 137-142.
4. Sagnelli E, Coppola N, Scolastico C et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-1110.
5. Villa E, Grotolla A, Butaffoco P et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96: 2973-2977.
6. Weltman MD, Brotodihardjo A, Crewe EB et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45.
7. Chiaramonte M, Stroffolini T, Vian A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-2137.
8. Berasain C, Betes M, Panizo A et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000; 47: 429-435.
9. Fukuda R, Ishimura N, Kushiyama Y et al. Hepatitis B virus X gene mutation is associated with the majority of serologically "silent" non-B, non-C chronic hepatitis. Microbiol Immunol 1996; 40: 481-488.
10. Uchida T, Shimojima M, Gotoh K, Shikata T, Tanaka E, Kiyosawa K. "Silent" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol Immunol 1994; 38: 281-285.
11. Zhang YY, Hansson BG, Kuo LS, Widell A, Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 1993; 17: 538-544.
12. Shiota G, Oyama K, Udagawa A et al. Occult hepatitis B virus infection in HBsAg-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol 2000; 62: 151-158.
13. Chemin I, Zoulim F, Merle P et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001; 34: 447-454.
14. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26.
15. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486.
16. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257.
17. Pontisso P, Ruvoletto MG, Fattovich G et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-1533.
18. De Maria N, Colantoni A, Friedlander L et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95: 3529-3536.
19. Kazemi-Shirazi L, Petermann D, Muller C. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol 2000; 33: 785-790.
20. Nirei K, Kaneko M, Moriyama M, Arakawa Y. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 2000; 43: 95-101.
21. Fukuda R, Ishimura N, Niigaki M et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58: 201-207.
22. Uchida T, Kaneita Y, Gotoh K et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus; probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol 1997; 52: 399-405.
23. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998; 54: 249-255.
24. EASL. International consensus conference on hepatitis B, 13-14 September 2002, Geneva, Switzerland, Consensus statement. J Hepatol 2003; 38: 533-540.
25. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-355.
26. Fukuda R, Ishimura N, Hamamoto S et al. Co-infection by serologically silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001; 63: 220-227.
27. Kubo S, Tamori A, Ohba K et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci 2001; 46: 2408-2414.
28. Giannini E, Ceppa P, Botta F et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver 2003; 23: 12-18.
29. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-4071.
30. Liaw YF, Chien RN, Lin SM et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997; 17: 449-452.
31. Dalekos GN, Kistis KG, Boumba DS et al. Increased incidence of anticardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to antiphospholipid syndrome. Eur J Gastroenterol Hepatol 2000; 12: 67-74.
32. Dalekos GN, Achenbach K, Christodoulou D et al. Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection. Heart 1998; 80: 270-275.
33. Zachou K, Liaskos C, Christodoulou DK et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003; 33: 161-168.
34. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numeric scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology 1981; 1: 431-435.
35. Mutimer DJ, Harrison RF, O'Donnell KB et al. Hepatitis C virus infection in asymptomatic British blood donor. J Viral Hepat 1995; 2: 47-53.
36. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology 1994; 19: 1321-1324.
37. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in north-western Greece. Transfusion 2001; 41: 652-658.
38. Ohkawa K, Hayashi N, Yuki N et al. Long term follow up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 1995; 46: 258-264.
39. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during hepatitis B virus infection. J Infect Dis 1992; 165: 831-834.
40. Squadrito G, Orlando ME, Pollicino T et al. Virological proflies in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 2002; 97: 1518-1523.
41. Jardi R, Rodriguez F, Buti M et al. Role of hepatitis B, C and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 404-410.
42. Schuttler CG, Fiedler N, Schmidt K et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37: 855-862.
43. Shih CM, Chen CM, Chen SY, Lee YH. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995; 69: 1160-1171.
44. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23: 14-20.
45. Stransky J, Malina L, Cieslarova B et al. Overt and hidden co-infection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda. Acta Virol 2000; 44: 23-28.
46. Colombari R, Dhillon AP, Piazzola E et al. Chronic hepatitis in multiple virus infection: histopathological evaluation. Histopathology 1993; 22: 319-325.
47. Tamori A, Nishiguchi S, Kubo S et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol. 2003; 69: 475-481.
48. Goritsas CP, Athanasiadou A, Arvaniti A, Lampropoulou-Karatza C. The leading role of hepatitis B and C viruses as risk factors for the development of hepatocellular carcinoma. A case-control study. J Clin Gastroenterol 1995; 20: 220-224.
49. Kuper HE, Tzonou A, Kaklamani E et al. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control 2000; 11: 171-175.
50. Kouroumalis EA, Skordilis PG, Moschandrea J et al. Natural history of advanced hepatocellular carcinoma in Crete. Association with hepatitis C virus. Eur J Gastroenterol Hepatol 1997; 9: 981-988.
51. Zignego AL, Fontana R, Puliti S et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51: 313-318.